|
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation |
Bergh M, Marais CA, Miller-Janson H, Salie F, Stander MP |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Bergh M, Marais CA, Miller-Janson H, Salie F, Stander MP. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. South African Medical Journal 2013; 103(4): 241-245 Indexing Status Subject indexing assigned by NLM MeSH Aged; Aged, 80 and over; Anticoagulants /economics /therapeutic use; Antithrombins /economics /therapeutic use; Atrial Fibrillation /complications; Benzimidazoles /economics /therapeutic use; Cost-Benefit Analysis; Dabigatran; Drug Costs; Female; Humans; International Normalized Ratio /economics; Male; Markov Chains; Myocardial Infarction /economics /etiology /prevention & Quality-Adjusted Life Years; South Africa; Stroke /economics /etiology /prevention & Warfarin /economics /therapeutic use; beta-Alanine /analogs & control; control; derivatives /economics /therapeutic use AccessionNumber 22013016627 Date bibliographic record published 07/06/2013 |
|
|
|